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Abstract: Modification of the Small Ubiquitin-like Modifier (SUMO) (SUMOylation) appears to regulate diverse cellular 
processes, including nuclear transport, signal transduction, apoptosis, autophagy, cell cycle control, ubiquitin-dependent 
degradation and gene transcription. Glycogen synthase kinase 3 GSK 3is a serine/threonine kinase that is thought to 
contribute to a variety of biological events, including embryonic development, metabolism, tumorigenesis, and cell death. 
GSK 3is a constitutively active kinase that regulates many intracellular signaling pathways by phosphorylating sub-
strates such ascatenin.We noticed that the putative SUMOylation sites are localized on K
292 residue
 of 
291FKFPQ
295 in 
GSK 3 based on analysis of the SUMOylation consensus sequence. In this report, we showed that the SUMOylation of 
GSK 3 occurs on its K
292 residue, and this modification promotes its nuclear localization in COS-1. Additionally, our 
data showed that the GSK 3 SUMO mutant (K292R) decreased its kinase activity and protein stability, affecting cell 
death. Therefore, our observations at first time suggested that SUMOylation on the K
292 residue of GSK 3  might be a 
GSK 3  regulation mechanism for its kinase activation, subcellular localization, protein stability, and cell apoptosis. 
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INTRODUCTION 
  SUMO (Small Ubiquitin-like Modifier) modification 
(SUMOylation) of proteins, especially of transcriptional 
regulators and nuclear pore proteins has been described [1]. 
SUMO is a new covalent modification leading to attachment 
of SUMO to specific lysine residues of target proteins [2, 3]. 
SUMO represents a class of ubiquitin-like proteins conju-
gated, like ubiquitin, by a set of enzymes to cellular proteins 
[5]. However, SUMOylation does not promote protein deg-
radation and distinct enzymes are involved in SUMOylation. 
For SUMOylation of substrate proteins, SAE1/SAE2 het-
erodimer acts as an E1 enzyme in mammals (Aos1/Uba2 in 
yeast), and Ubc9 acts as an E2 SUMO-conjugating enzyme 
[6]. The mammalian PIAS (protein inhibitor of activated 
STAT) family, Ran Bp (Ran binding protein) 2 and the poly-
comb PC2 repressor, have recently been shown to function 
as E3-type SUMO ligases [7-10]. The analysis of many 
SUMOylation substrates indicates that it occurs at a particu-
lar sequence, thus the specificity of SUMO conjugation 
might be conferred by recognition of this sequence by the  
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thioester-linked Ubc9–SUMO conjugate [11-13]. Lysine 
residues targeted for SUMOylation are often found within 
specific sequences, such as its consensus sequence [5, 14]. 
  Glycogen synthase kinase 3  (GSK 3) is a constitu-
tively active serine/threonine kinase that regulates many in-
tracellular signaling pathways by phosphorylating substrates 
such as -catenin [15, 16]. The phosphorylation of -catenin 
by GSK 3 is facilitated by the scaffold protein axin and is 
inhibited either by GSK 3-binding protein (GBP), also 
known as Frat (Frequently rearranged in advanced T-cell 
lymphomas), or Dishevelled. The phosphorylation of -
catenin by GSK 3, resulting in its ubiquitin-mediated prote-
olysis, is the axis of the canonical Wnt signaling pathway. 
Thus, GSK 3 is thought to contribute to a variety of bio-
logical events, such as embryonic development, metabolism, 
tumorigenesis, and cell death [17]. The function of GSK 
3 is also regulated through phosphorylation by other protein 
kinases including Akt, which is a serine/threonine kinase that 
is activated by phosphatidylinositol 3-kinase (PI3K) signal-
ing and phosphorylates GSK 3 on S
9, thereby inactivating it 
[18, 19].  
  During our investigation of the Akt-GSK 3 signal trans-
duction pathway, we noticed the putative SUMOylation site 
(K
292  in 
291FKFPQ
295) in GSK 3 using consensus motif 
computer analysis (http://www.abgent.com/doc/sumoplot). 
This finding led us to evaluate whether GSK 3 is SUMOy-68    The Open Biochemistry Journal, 2008, Volume 2  Lee et al. 
lated or not. And then, we observed the SUMOylation of 
GSK 3 with in vitro or in vivo SUMOylation assay. Addi-
tionally, we identified that the SUMOylation site of GSK 3 
is the K
292 residue using site directed mutagenesis analysis. 
We also characterized the biological significances of GSK 
3 SUMOylation using a GSK 3 kinase assay, confocal 
microscopy and FACS analysis. Therefore, in this article, 
our data suggest that SUMOylation in GSK 3 is one of the 
regulation mechanisms for kinase activity, protein stability, 
and nuclear localization, as well as affecting cell apoptosis. 
Even though it is unclear how SUMOylation of GSK 3 oc-
curs in the cell, we suggest here that SUMOylation on the 
K
292 residue of GSK 3 seems to be a new mechanism for its 
functional regulation.  
MATERIALS AND METHODS 
Cell Culture 
  COS-1 was purchased from ATCC (Manassas, VA, 
USA). Media and supplements were obtained from GIBCO 
(Grandisland, NY, USA). The cell line was maintained in 
Dulbecco’s Modified Essential Medium (DMEM) containing 
10% heat inactivated (for 30 min at 56) fetal bovine serum 
(FBS), 100 U potassium penicillin/ml, 100 μg streptomy-
cin/ml, 2 mM glutamine and 20 mM sodium bicarbonate. 
The cells were incubated at 5% CO2, 95 % humidity and 
37 and growth medium changed every 3 days. SUMO 
fusion protein was obtained from Calbiochem (Grandisland, 
NY). Wild type human GSK 3 was purchased in Ha- or 
GST-tagged mammalian expression vector (GeneCopoeia 
Co. CA, USA). 
Antibodies 
  Monoclonal antibody against the Ha epitope or GST was 
purchased from Santa Cruz Biotech. Inc. (Santa Cruz, CA, 
USA). Antibodies against GSK 3 or human Tau specific 
antibody were purchased from Santa Cruz Biotech. Inc. 
(Santa Cruz, CA, USA). actin antibody was purchased from 
Cell Signaling Technology, Inc. (Cell Siganling Co. MA, 
USA). Antibodies against Tau 422 Ser phosphor was pur-
chased from Calbiochem. (La Jolla, CA, Germany). Anti-
bodies against SUMO-1 was purchased from ABGENT ( 
San Diego, CA, USA). 
Site-Directed Mutagenesis of GSK 3 
  To generate GSK 3, K292R, and K340R (UP; 5’-aac tac 
aca gaa ttt aGG ttc cct caa att aag gca-3’, Down; 5’-aat ttg 
agg gaa CCt aaa ttc tgt gta gtt tgg gtt-3) and (UP; 5’- cgg gac 
cca aat gtc aGG cta cca aat ggg cga gac-3’, Down 5’- ccc att 
tgg tag CCt gac att tgg gtc ccg taa ttc-3) from GSK 3  were 
used [20] with a “Chameleon” double-stranded site-directed 
mutagenesis kit (Stratagene, CA, USA), according to the 
manufacturer’s instructions. Every mutation was confirmed 
by DNA sequencing.  
GSK 3 Expression Vector Transfection and Purification 
  For mammalian expression, Ha-GSK 3 wt or GSK 3 
SUMO mutant construct were transfected into COS-1 cells 
using the lipofectin transfection method (Gibco-BRL Co). 
Transfected cells (2x10
7) were lysed in RIPA lysis buffer. 
Anti-Ha monoclonal antibody was incubated with 1000 μl of 
pre-cleaned cell lysate and precipitated with protein A aga-
rose beads. The beads were then washed three times with 
excess cell lysis buffer and the final pellet used for the im-
muno assay to detect SUMOyaltion. Western blots were per-
formed with anti-SUMO-1 antibody to
 detect the presence of 
SUMO [3, 21]. To detect the phosphorylation of GSK 3  
T
216 residue, an anti-216 Tyr phospho Ab (La Jolla, CA, 
Germany) was used. 
Double Immunofluorescence Microscopy 
  COS-1 cells were plated at a low confluence (~30%) on 
two-well Lab-Tek Permanox slides (Nalgene
 Nunc Interna-
tional, Naperville, IL) and transiently transfected
 with Ha –
GSK 3 wt or Ha-GSK 3 SUMO mutant (K292R) plasmid 
using
  the lipofectamine procedure.
  Cells were starved for 
36 h and subsequently treated with
 10% calf serum for 15 h. 
At no time did cell confluency exceed 60%. Cells were 
fixed, permeabilized, and processed for indirect
 double im-
munofluorescence microscopy as described previously, with
 
minor modifications. Cells were blocked in
 normal goat and 
diluted (1:30) in PBS for 15 min, then incubated
 with affin-
ity-purified, anti- antibodies at 1:150 dilution
 in combination 
with a 1:1000 dilution of murine SUMO-1 monoclonal
 anti-
bodies (ABGENT, San Diego, CA, USA), anti- GSK 3 S
9 
residue, an anti-9 Ser phospho Ab (purchased from Cell Si-
ganling Co. MA, USA), or Ha monoclonal antibodies (Santa 
Cruz, CA, USA) at room temperature for 1-2 h on a rocking 
platform. Washed slides were then incubated for 1 h at
 room 
temperature with 1:150 dilutions of both anti-rabbit fluo-
rescein
  isothiocyanate-conjugated secondary antibody (Mo-
lecular Probes
 Inc. OR, USA) and Texas red-conjugated goat 
anti-rabbit secondary
  antibody (Molecular Probes Inc. CA, 
USA). Slides were washed and then
  mounted with Vec-
tashield mounting medium (Vector Laboratories
  Inc. CA, 
USA) and examined using Leica TCS SP AOBS in The 
Core Facility of Chungbuk National University [20]. 
Expression and Purification of Recombinant Proteins 
  GST tagged GSK 3 wt was purchased from GeneCopia 
TM and its SUMO mutant (K292R) was cloned with the 
same primer set used for generation of mammalian SUMO 
mutants. GST tagged protein was expressed in Escherichia 
coli BL21 and purified with GST-agarose beads according to 
the manufacturer’s instruction (Amersham Biosciences Co). 
Purified proteins were used for the SUMOylation assay sub-
strate protein.  
In vitro SUMO-1 Conjugation Assay 
  SUMO-1 conjugation assay was performed in vitro using 
the SUMO assay kit purchased from Corgen Inc (Taipei, 
Taiwan), according to the manufacturer’s recommended pro-
tocol. One microgram of purified GST-tagged GSK 3 mu-
tants were mixed with 250 ng of Ubc9, 125 ng of 
Aos1/Uba2, with or without 2 g of SUMO-1, then incu-
bated for 2 hr at 30°C in the presence of 50 mM Tris [pH 
7.5], 5 mM MgCl2, with or without (for the negative control) 
2 mM ATP in a 20 l volume. Reactions were stopped with 
SDS-PAGE sample buffer and SUMO conjugates separated 
by SDS-PAGE and analyzed by western blotting using the 
mouse monoclonal antibody against SUMO-1 to detect GSK 
3 [3]. The relative optical density (OD) was measured by 
image analysis of the dried SDS-PAGE gel using the Fuji Small Ubiquitin-Like Modifer Modification of Glycogen Synthase Kinase 3 on its K
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Image Quant software (Fujifilm, Tokyo, Japan), according to 
the manufacturer’s instructions. 
GSK 3 Kinase Assay 
  Human Tau protein was purchased from Biomol (CA, 
USA).  GSK 3 kinase assays were performed for 30 minutes 
at 30 °C in a 25-l reaction volume containing [20 mM 
HEPES, pH 7.2, 10 mM MgCl2, 10 mM MnCl2, 1 mM 
dithiothreitol, 0.2 mM EGTA, and 1 μg phosphatidylserine], 
and 1g human Tau protein as a GSK 3 substrate protein. 
The phosphorylated Tau protein was detected using a West-
ern blot with Tau S
422 phosphor specific antibody, purchased 
from Calbiochem (La Jolla, CA, Germany).  
 
Protein Stability Experiments 
  COS-1 cells (2.5  10
5 cells per well) in 10cm plates 
were transfected with 1.0 μg of expression vector with Ha-
GSK 3 wt or SUMO mutant plasmid. The medium was 
replaced with medium containing 200 μg/ml cycloheximide 
36 h after transfection (0-h time point). Cell lysates were 
harvested at 0, 8, 16, and 24 h then analyzed by immunopre-
cipitation and Western blotting using anti-Ha antibodies, and 
assayed in five time repeats. The relative optical density 
(OD) was measured by image analysis of the dried SDS-
PAGE gel with the Fuji Image Quant software (Fujifilm, 
Tokyo, Japan), according to the manufacturer’s instructions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). GSK 3 functional domain and SUMOylation.  
The Glycogen synthase kinase 3 (GSK 3 functional domains (its protein kinase and FRAT/Axin binding domain) and the putative SU-
MOylation site (K
292 in 
291FKFPQ
295) is indicated (A). GSK 3 SUMO mutant (K292R) was constructed by site directed mutagenesis. GSK 
3  SUMO mutant (K292R) was inserted into GST fusion (for bacteria) and Ha fusion (for cell line) expression vectors. (B) GSK 3 wild 
type (wt) protein that was purified from E. coli was incubated with a SUMOylation assay kit (See Material and method). For the negative 
control, the same assay conditions were used without ATP (right lane). A western blot of the same sample was performed with GSK 3 
monoclonal antibody to monitor the protein amount in the experiment (at bottom). SUMOylated GSK 3, as several high molecular weight 
protein bands, was indicated. (C) A western bolt of the immunopurified GSK 3 from COS-1 was performed using the SUMO-1 specific 
antibody. SUMOylation of GSK 3 was detected as high molecular weight protein bands, as indicated (left lane). For the negative control, an 
unrelated mouse antibody was used (right lane). To monitor the total protein amount to be used in the cell lysates, the western blot was per-
formed with actin monoclonal antibody (bottom). (D) Confocal microscopic analysis of endogenous GSK 3 wt (green color) and SUMO-1 
(red color). GSK 3 was detected in both the cytoplasm and nuclear region. The SUMO-1 modification proteins were mainly detected in the 
nuclear region (yellow color). All the figures in this article represent results from three experiments repeated independently.  
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FACS Analysis 
 Ha-GSK  3 (wt), Ha-GSK 3 SUMO mutant (K292R), 
or pcDNA vector was transfected and the rate of apoptosis 
measured by Annexin V-PE apoptosis detection kit I (BD 
Biosciences, CA, USA), according to the manufacturer’s 
instructions. Transfected Cells were washed twice in cold 
PBS and then resuspended in Binding buffer (0.01 M 
Hepes/NaOH (pH 7.4) 0.14 M Nacl, 2.5 mM CaCl2). 1X10
5 
cells in 100 μl were transferred to 5ml culture tube and adde 
5 μl of Annexin V-PE and 5 μl of 7-Amino-actinomycin D. 
The cells were vortexed gently and incubated for 15 min at 
25 °C in the dark. 400 μl of binding buffer was added to 
each tube. Within 1 hr, FACS was performed on a Coulter 
Epics Elite equipped with a gated amplifier and upgraded 
with enhanced system performance in The Core Facility of 
Chungbuk National University [20].  
RESULTS 
SUMOylation of GSK 3 In Vitro and In Vivo 
  Using computer analysis of the SUMOylation consensus 
sequence from GSK 3, two sites were found in the C-
terminal domain (K
292 in 
291FKFPQ
295), which is near by the 
Axin and FRAT binding domains (262-299aa), as shown in 
Fig. (1A) [22, 23]. Therefore, we predicted that GSK 3 is 
one of the SUMO modified (SUMOylation) proteins [3, 13]. 
To test our prediction, we constructed GSK 3 SUMO mu-
tant (K292R) which is indicated in Fig. (1A) below, by site 
directed mutagenesis. Both the GSK 3 wild type (wt) and 
SUMO mutant (K292R) was inserted into Ha tagged expres-
sion vector (for eukaryotic cell) or GST fusion expression 
vector (for prokaryotic cell). 
  Initially we performed the in vitro SUMOylation assay 
using GST-GSK 3 fusion protein purified from E. coli to 
determine whether SUMOylation of GSK 3 occurred, as 
described in the Materials and Methods section [21], using a 
SUMO assay for GSK 3 wt without ATP as a negative con-
trol (Fig. 1B, right lane). The western blot of each sample 
was performed using GSK 3 antibody to monitor the pro-
tein amount in the experiment (at bottom). As shown in Fig. 
(1B), SUMOylated GSK 3 was detected, including several 
high molecular weight protein bands (left lane), suggesting 
that GSK 3 is one of SUMOylation proteins in vitro. 
  To confirm GSK 3 SUMOylation in the cell, we per-
formed a western bolt of the immunopurified GSK 3 from 
COS-1 cells with SUMO-1 specific antibody, as described in 
the Materials and Methods section [21]. As shown in Fig. 
(1C), SUMOylation of GSK 3 was detected as high mo-
lecular weight protein bands (left lane), similar to the results 
in Fig. (1B). An unrelated mouse antibody was used as a 
negative control (right lane). To monitor the total protein 
amount to be used in the cell lysates, western blot was per-
formed with actin monoclonal antibody (Fig. 1C, bottom). 
Therefore, the results depicted in Fig. (1C) also suggest that 
GSK 3 was SUMOylated in COS-1 cells, which is consis-
tent with the results in Fig. (1B).  
  Confocal microscopy observation of COS-1 cells with 
GSK 3 or  SUMO1 specific antibody was used to observe 
whether endogenous GSK 3 undergoes SUMOylation in the 
cell. As shown in Fig. (1D), GSK 3, which was detected in 
both the cytoplasm and the nucleus, was merged with 
SUMO-1 in the nucleus. These results suggest that endoge-
nous GSK 3 in COS-1 was modified by SUMO-1, which is 
consistent with Fig. (1B and C). Interestingly, SUMOylation 
of GSK 3 seems to be required for its nuclear localization 
(Fig. 1D). Therefore, overall, these results (Fig. 1A, B, C, 
and D) suggest that GSK 3 is one of the SUMOylation pro-
teins. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). SUMOylation Site in GSK 3. 
(A) The purified GST-GSK 3 wt or GST-GSK 3 SUMO mutant (K292R) fusion protein was used as the substrate protein in the SUMOy-
lation assay as described in the Materials and Methods section. The SUMOylation of GSK 3 wt was detected as a high molecular weight 
protein band (left lane), whereas its SUMO mutant was totally inhibited, as shown (right lane). (B) Ha –GSK 3 wt or Ha –GSK 3 SUMO 
mutant was transfected to COS-1 cells and immunoprecipitated with Ha mouse monoclonal antibody. The immunoprecipitants were sub-
jected to the western bolt with SUMO-1, as described in the Materials and Methods section. The SUMOylation of GSK 3 wt was indicated 
as several high molecular weight protein bands (left lane), whereas its SUMO mutant was totally inhibited (right lane). To monitor the GSK 
3 protein expression, the immunoprecipitants were subjected to the western bolt with GSK 3  polyclonal antibody  (bottom). 
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SUMOylation Sites in GSK 3 
  As shown in Fig. (1A), we predicted that K
292  in 
(
291FKFPQ
295) of GSK 3 was the putative SUMOylation 
sites based on consensus sequence analysis. To test our pre-
diction, we performed the SUMOylation assay in vitro with 
GSK 3 SUMO mutant (K292R). We used GST fusion GSK 
3 (wt) or GSK 3 SUMO mutant, as the substrate protein. 
Western blotting of the same sample was performed with 
GST monoclonal antibody to monitor the amount of protein 
in the experiment (at bottom). We also performed the SU-
MOylation assay using GST fusion, GSK 3  K292R mutant 
protein, and did not observe the SUMOylation of each mu-
tant protein (data not shown). As shown in Fig. (2A), the 
SUMOylation of GSK 3 SUMO mutant was not detected, 
whereas that of GST fusion GSK 3 (wt) was observed. 
Therefore, our data suggested that K
292 in (
291FKFPQ
295) of 
GSK 3 is the putative SUMOylation sites.  
  To confirm our observation further, we performed a 
western bolt using the immunopurified Ha-GSK 3 wt or Ha 
-GSK 3 SUMO mutant (K292R)  from COS-1 cells (Fig. 
2B), using the SUMO-1 specific antibody. To monitor the 
total protein amount to be used in the cell lysates, western 
blot was performed using GSK 3 polyclonal antibody (bot-
tom) (Fig. 2B). As shown in Fig. (2B), SUMOylation of 
GSK 3 wt was detected as high molecular weight protein 
bands (right lane), whereas GSK 3 SUMO mutant (K292R) 
was not. Thus, as indicated in Fig. (2A and B), these data 
suggest that SUMOylation of GSK 3 occurs on K
292 residue
 
in 
291FKFPQ
295. 
Confocal Microscopic Analysis with GSK 3 SUMO Mu-
tant 
  Next, we indented to determine the biological signifi-
cance of SUMOylation on K
292 of GSK 3. ecause the con-
focal microscopy results in Fig. (1D) suggested that SU-
MOylation of GSK 3 occur in the nuclear region, we first 
determined whether SUMOylation of GSK 3 affects its 
subcellular localization. We performed the confocal micro-
scopic analysis with Ha -GSK 3 wt or the SUMO mutant 
construct, as described in Fig. (1A). The transfected Ha –
GSK 3 wt or Ha –GSK 3 SUMO mutant (K292R) was 
detected as green and the SUMO-1 position was detected as 
red using fluorescence microscopy (Fig. 3). Similar to the 
results shown in Fig. (1D), SUMO-1 signals were mainly 
detected in the nucleus (Fig. 3A middle lane). Ha -GSK 3 
wt was observed in both the cytoplasm and nucleus, similar 
to the results shown in Fig. (1D). However, the merged be-
tween GSK 3 with SUMO-1 (yellow color) was detected in 
the nucleus and not the cytoplasm (Fig. 3A right lane), sug-
gesting that SUMOylation of GSK 3 is related to its nuclear 
subcellular localization. This result also supports the idea 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (3). Confocal microscopic analysis of GSK 3 wt or its SUMO mutant 
Confocal microscopic analysis of transfected Ha –GSK 3 wt (A), Ha –GSK 3 SUMO mutant (K292R) (B) was performed to determine 
whether it merged with SUMO-1 (red color). All Ha –GSK 3 constructs were shown as green color. The transfected Ha -GSK 3 wt (de-
tected in both the cytoplasm and the nucleus) merged (yellow) with SUMO-1 in the nucleus (A). The transfected Ha –GSK 3 SUMO mu-
tant was detected in the cytoplasm, but not in the nucleus (B). The SUMO-1 modification proteins were mainly detected in the nuclear region 
(B middle lane). GSK 3 SUMO mutant in which the SUMOylation site was eliminated was not merged with SUMO-1 in the nucleus (B 
right lane).  
Ha GSK 3β wt  Merge SUMO-1
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B
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that GSK 3 is one of the SUMOylation proteins, consistent 
with the results presented in Fig. (1D).  
  Surprisingly, Ha –GSK 3 SUMO mutant was mainly 
detected in the cytoplasm, not the nucleus, and was not 
merged (yellow color) with SUMO-1 in the nucleus (Fig. 3B 
right lane). Therefore, these results suggested that SUMOy-
lation of GSK 3 is required for its nuclear localization, con-
sistent with Fig. (1D and 3A). Further, consistent with the 
results shown in Fig. (2), this result (Fig. 3B) again con-
firmed that K
292 of GSK 3 is SUMOylation sites by the 
confocal microscopic analysis. 
SUMOylation of GSK 3 is Required for its Kinase Acti-
vation 
  To further define the biological significance of GSK 3 
SUMOylation, we compared the kinase activity of GSK 3 
with that of the GSK 3 SUMO mutant. Each Ha –GSK 3 
wt or its SUMO mutant (K292R) expression vector was 
transfected into COS-1 cells, and immunoprecipitated with 
Ha monoclonal Ab. To monitor the expression of Ha -GSK 
3 wt or GSK 3 SUMO mutants, western blot was per-
formed with an anti-GSK 3 antibody (Fig. 4A). Because it 
has been reported that 216 tyrosine residue phosphorylation 
of GSK 3 is required for its activation [17, 24], we moni-
tored it with its 216 tyrosine phosphorylation specific anti-
body (Fig. 4B). As shown in Fig. (4B), we observed that 216 
tyrosine phosphorylation of the Ha -GSK 3 SUMO mutant 
was reduced compared to that of Ha –GSK 3 wt (Fig. 3B), 
even though the expressed protein amount was almost same 
(Fig.  4A). Next, we measured the kinase activity with its 
substrate protein Tau, because Ser 422 of human Tau is 
phosphorylated by GSK 3  [25, 26]. As shown in Fig. (4C), 
we observed that the kinase activity of the GSK 3 SUMO 
mutant was reduced to half that of the GSK 3 wt, consistent 
with its 216 tyrosine phosphorylation result (Fig. 3B). Taken 
together, our data suggest that SUMOylation of GSK 3 is 
also required for not only its 216 tyrosine phosphorylation, 
but also its kinase activity. To eliminate cell line specificity, 
we performed the experiment using NIH 3T3 cells and ob-
tained the same results (data not shown). 
The Effect of GSK 3 SUMOylation on Protein Stability 
  To evaluate the effect of SUMOylation on GSK 3 pro-
tein stability, we performed the pulse-chase experiments as 
described in the Materials and Methods section. Each Ha -
GSK 3 (wt or SUMO mutant) expression vector was trans-
fected into COS-1 cells and immunoprecipitated with Ha 
monoclonal Ab following cyclohexamide treatment (Fig. 
5A). GSK 3 proteins were chased for the indicated time 
periods (0, 8, 16, 24 hr), and then immunoprecipitated with a 
polyclonal anti- Ha antibody and subjected to SDS-PAGE 
followed by western blot with GSK 3 antibody. To control 
the protein amount, we monitored the actin in each sample 
by western blotting (Fig. 5A). The quantification of the 
pulse-chase experiment, as determined by image analysis of 
the dried SDS-PAGE gel using the Fuji Image Quant soft-
ware, is shown in Fig. (5B). As shown in Fig. (5), the protein 
stability of the GSK 3 wt was twice that of the GSK 3 
SUMO mutant, suggesting that SUMOylation on the K
292 of 
GSK 3 seems necessary for protein stability. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Kinase activity of GSK 3  wt or its SUMO mutant. 
 The immunopurified Ha -GSK 3 wt or its SUMO mutant (K292R) protein with Ha Ab from COS-1 was immunoblotted with GSK 3 (A) 
or Anti- GSK 3 Tyr 216 phospho Ab polyclonal antibody (B). The relative optical density (OD), as determined by image analysis with the 
Fuji Image Quant software, is indicated below. The GSK 3 kinase activity was measured using human Tau protein as a substrate (C). S
422 
residue phosphorylation of human Tau protein was detected with its specific antibody. The relative GSK 3 activity by image analysis with 
the Fuji Image Quant software is indicated below. Results shown are one of five repeated experiments  
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The Effect of GSK 3 SUMOylation on Cell Viability 
  We measured cell viability using FACS analysis to de-
termine whether SUMOylation on K
292 of GSK 
3 influenced cell viability. As shown in Table 1, the FACS 
results indicate that the GSK 3 SUMO mutant (K292R) 
increased the cell survival rate significantly compared to the 
Ha -GSK 3 wt or pcDNA vector alone. Thus, GSK 
3 SUMO mutant was only less effective on apoptosis than 
the Ha -GSK 3 wt or pcDNA vector alone (Table 1).  
Table 1.  Cell viability of GSK 3 wt and its SUMO mutant. 
GSK 3 construct   Rate of apoptosis (%) Be FACS 
Ha-GSK3  (wt)  25 +/- 3 
Ha-GSK3  (SUMO mutant)  5 +/- 2 
pcDNA (vector only)  10 +/- 2 
Ha -GSK 3 (wt) or (SUMO mutant, K292R) or pcDNA vector was transfected and the 
rate of apoptosis measured by FACS. Ha -GSK 3 SUMO mutant (K292R), which was 
dominantly localized in the cytoplasm, promoted cell survival (but not cell apotosis) 
when compared to GSK 3 wt constructs. Results shown are the average of five re-
peated experiments. For details, see the Materials and Methods section. 
  In summary, our results indicate that SUMOylation on 
K
292 of GSK 3 regulates protein stability, kinase activity, 
nuclear localization, and cell apoptosis. Therefore, our ob-
servations suggest that SUMOylation is a GSK 3 functional 
modification for its regulation. 
DISCUSSION 
  Because GSK 3 is a multi-functional protein kinase that 
may regulate biological functions, such as embryonic devel-
opment, metabolism, tumorigenesis, and cell death, by regu-
lation of many intracellular signaling pathways through 
phosphorylation substrates, such as -catenin, the characteri-
zation of GSK 3 modification is essential to understand its 
function and regulation [15-17]. 
  To understand the modification of GSK 3, we first 
tested whether GSK 3 is a SUMOylated protein or not. Af-
ter computer analysis of the SUMOylation motif indicated 
that GSK 3 seems to be SUMOyalted, we confirmed that 
GSK 3 is one of the SUMOylated proteins by conducting a 
SUMOylation assay, and through confocal microscopy 
analysis (Fig. 1D and 3). After confirming that GSK 3 is a 
SUMOylated protein, we intended to know which lysine 
residues of GSK 3 are SUMOylated. To do so, we per-
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Protein stability of GSK 3 wt and its SUMO mutant. 
Ha –GSK 3 or GSK 3 SUMO mutant (K292R) was transfected into COS-1 cells and the cells treated with cyclohexamide. The GSK 3 
proteins were chased for the indicated time periods. Ha–GSK 3 proteins were immunoprecipitated with a polyclonal anti- Ha antibody and 
subjected to SDS-PAGE followed by western blotting with a monoclonal GSK 3 antibody (A). To monitor the protein amount, an equal 
amount of cell lysate was subjected to western blotting with an actin antibody. Results shown are one of five repeated experiments. Quantifi-
cation of the pulse-chase experiment is shown in (B) by image analysis with the Fuji Image Quant software.  
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formed site directed mutagenesis using computer SUMOy-
altion consensus motif analysis (Fig. 1A) and found that 
SUMOylation occurs on the K
292 in 
291FKFPQ
295 of GSK 3  
(Fig. 2 and 3). Next, to identify the biological significance of 
GSK 3 SUMOylation, we compared its protein kinase ac-
tivity, subcellular localization, and stability with those of the 
GSK 3 SUMO mutant and found that SUMOylation of 
GSK 3 affected its biological roles, including protein kinase 
activity, subcellular localization, stability, and cell viability. 
(Fig.  3-5, Table 1). Therefore, although the molecular 
mechanism underlying GSK 3 SUMOylation and its regula-
tion remain unknown, our data suggest that SUMOylation 
occurs on GSK 3 protein as a novel posttranslational step 
for GSK 3 functional regulation. Further studies are essen-
tial to elucidate the molecular mechanism involved in GSK 
3 mediated signal transductions through SUMOylation. In 
particular, it will be important to determine exactly when and 
where SUMOylation of GSK 3 occurs, as well as how it is 
regulated, because GSK 3 is involved in a variety of human 
diseases, including cancer and Alzheimer’s [22, 23, 27-29].  
  It has been reported that SUMO-1 (but not SUMO-2, 3 
and 4) monomerically conjugates the  amino group of the K 
residue in SUMO-1 acceptor consensus sequences [1, 2, 12, 
30]. As shown in Fig. (1B and C), however, the SUMOyla-
tion of GSK 3 wt was detected as several high molecular 
weight protein bands (~200 kD), which indicates that multi-
ple SUMOylation on several other K residues of GSK 3 
occurred. Even though SUMO forms a homo or hetero dim-
mer in the cell, SUMOyaltion by other SUMO isotypes 
(SUMO-2, 3 and 4) may be excluded in this experiment, 
because SUMO-1 monoclonal antibody was used. We no-
ticed several K residues in GSK 3 where multiple SUMOy-
lation was possible on GSK 3 by SUMO-1 [31]. However, 
it is presently unclear why SUMOylation of GSK 3 occurs 
as high molecular weight protein bands in vivo and in vitro 
in SUMOylation assays conducted using SUMO-1 specific 
antibody.  
  Our identification of and K
292 residue of GSK 3 as tar-
gets for the majority of SUMOylation will help determine 
whether it plays a role in the normal  catenin degradation 
assembly. Phosphorylation of -catenin by GSK 3 has been 
shown to be facilitated by the scaffold protein axin and is 
inhibited either by GSK3-binding protein (GBP), also known 
as Frat (Frequently rearranged in advanced T-cell lympho-
mas), or by Dishevelled [22, 23, 27-29]. Thus, basing on our 
results, which indicate that the GSK 3 SUMO mutant pro-
motes cell survival (Table 1), it seems that the GSK 
3 SUMO mutant facilitates its dissociation with axin but 
facilitates association with GBP/Frat or Dishevelled (thus 
staying in the cytoplasm), resulting in inhibition of phos-
phorylation of -catenin and its ubiquitin-mediated proteoly-
sis. SUMOylation on the K
292 residue of GSK 3 seems to 
regulate not only protein interaction with Frat/Axin, but also 
its activation. SUMOylation on the K
292 residue of GSK 3 
also seems to be one of the cell death signals (Table 1), re-
sulting from the increase of its protein stability and nuclear 
localization (Fig. 1D, Fig. 3). Therefore, we speculated that 
because GSK 3 is one of the major effectors of Wnt signal-
ing [15, 16, 17], SUMOylation on the K
292 residue of GSK 
3 affected cell survival (Table 1). Even though it is un-
known how SUMOylation of GSK 3regulates phosphory-
lation of its substrates, such as -catenin, we are now evalu-
ating the effect of GSK 3 SUMOylation on phosphorylation 
of -catenin, its stability and Wnt signaling. 
  It is presently unknown how GSK 3 is transported in the 
nuclear region, where SUMOylation occurs. Since GSK 3 
is known as a cytoplasmic and nuclear protein [32, 33], GSK 
3 seems to have its own nuclear localization sequence 
(NLS) or nuclear export sequence (NES). We did not notice 
any NLS or NES consensus sequence homology around the 
SUMOylation site, K
292 [34-36]. However, we can not rule 
out the possibility that our GSK 3 SUMO mutant (K292R) 
influences its own NLS or NES function directly or indi-
rectly, because of the diversity of the NLS or NES consensus 
sequence [34, 35]. 
  Even though it has been reported that accumulation of 
GSK 3  in the nucleus is related to the cell cycle, we do not 
presently know whether our results regarding GSK 3  nu-
clear localization and its SUMOylation is related to cell cy-
cle regulation [32, 33]. It has been demonstrated that Akt, 
which is activated by phosphatidylinositol 3-kinase (PI3K) 
signaling, phosphorylates GSK 3 on S
9, thereby inactivating 
it [18, 19]. Our preliminary data suggested that phosphoryla-
tion of GSK 3 on S
9 seems to be unrelated to SUMOylation 
(data not shown), however it is still unknown what types of 
cell signals stimulate SUMOylation of GSK 3 on K
292. Even 
though we performed the experiment using NIH 3T3 cells 
and observed the same results as described above, due to the 
possibility of cell line specificity, we can not say for certain 
that SUMOylation of GSK 3 on K
292 regulates its kinase 
activity, subcellular localization, protein stability, and apop-
tosis in normal cells. Further, we can not rule out the possi-
bility that the mutation on K
292 of GSK 3 affect directely on 
its protein kinase activity, regardless of its SUMOylation.  
  E1 enzyme, E2 SUMO-conjugating enzyme, and E3 
SUMO ligases involved in GSK 3 SUMOylation still re-
main to be characterized and there mechanism identified. 
Therefore, more studies will be required to elucidate the 
physiological significance of SUMOylation on K
292 residue 
of GSK 3. Because lysine serves as the attachment site for 
several modifications, including ubiquitination, acetylating, 
and methylamine [37], it seems important that multiple SU-
MOylation on other lysine residues of GSK 3, which is 
trigged by SUMOylation on the K
292 residue, also plays a 
role by antagonizing other post-translational modifications. 
Because the half-life of the GSK 3 SUMO mutant was re-
duced compared to that of the GSK 3 wt (Fig. 5), we specu-
lated that the GSK 3 SUMO mutant is more ubiqutinized 
than that of the GSK 3 wt. However, the relationship be-
tween SUMOyaltion and ubiquitinization (or other modifica-
tion) of GSK 3 also remains to be characterized. 
  Currently, four SUMO subtypes (SUMO-1, 2, 3 and 4) 
have been identified [5, 14, 38]. The SUMOylation consen-
sus sequences for each subtype are known to be the same as 
SUMO-1 (KxE/D, where  represents L, I, V or F and x is 
any amino acid) [11-13]. However, the K
292 residue
  in 
291FKFPQ
295of GSK 3 does not belong to the exact SU-
MOylation consensus sequences (KxE/D, where  repre-
sents L, I, V or F and x is any amino acid). We do not pres-
ently know how great an effect the difference between the 
GSK 3 amino acid sequence and the consensus sequences 
has on SUMOylation. Therefore, the SUMO subtypes that 
modify GSK 3 should be characterized, and the SUMOyla-Small Ubiquitin-Like Modifer Modification of Glycogen Synthase Kinase 3 on its K
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tion subtype that controls each specific GSK 3 function 
should be determined.  
  In conclusion, point mutagenesis analysis suggested that 
SUMOylation of GSK 3 occurs on its K
292 residue, which is 
overlapped with the Frat or Axin binding domain by SUMO-
1 (Fig. 1A), and SUMOylation of GSK 3 promotes
 its nu-
clear localization and protein stability, resulting in the stimu-
lation of cell apoptosis. Overall, our results suggest that 
SUMOylation on the K
292 residue of GSK 3  may be a new 
GSK 3  regulation mechanism for kinase activity, subcellu-
lar localization, protein stability, and apoptosis. Our findings 
may also provide a new intervention clue to cure the many 
human diseases caused by the abnormal regulation of GSK 
3 mediated signal transductions, such as cancers, diabetes, 
and Alzheimer’s disease. 
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